



# What if clinical research was an option on your **Lung Cancer** path?



Learn about the PolyDamas research study of an investigational combination of medications for people with metastatic non-small cell lung cancer (NSCLC).

## What is a clinical research study?

A clinical research study allows doctors to evaluate and learn about an investigational medication, which is a medication that is not approved by a country's health authorities for public use. Through a research study, doctors can gather information about an investigational medication, such as how safe and effective it may be.

Using the information collected in a research study, doctors and regulatory health authorities can determine if an investigational medication could potentially treat people with a certain condition, disease or disorder.

To conduct a research study, doctors need people like you to participate. Please know that your participation in a research study is voluntary and not a part of your standard medical care.



## What is the purpose of the PolyDamas study?

In this study, doctors want to learn about the safety and efficacy of an investigational combination of medications for adults with metastatic non-small cell lung cancer (NSCLC). This investigational combination has not been approved by any regulatory health authority for the treatment of metastatic NSCLC. It is only available to people who participate in research studies like this one.

The results of this study will provide more information about the investigational combination of medications and its use in patients with metastatic NSCLC.

## What will happen during the PolyDamas study?

If you are eligible and choose to participate, you will receive the investigational combination of medications during repeating 28-day cycles. One investigational medication will be given through intravenous (IV) infusions weekly for the first 4 weeks and once every 2 weeks thereafter. The other investigational medication is given through IV infusion once every 2 weeks. The study doctor will talk with you more about the investigational medications, how you will receive them and when you will receive them.

Your total participation in this study will last as long as the study doctor believes that you are benefitting from it. Throughout the study, you will also visit the study clinic regularly for health exams and tests.

## Who is eligible for the PolyDamas study?

**You may be able to participate in this study if you:**

- Are 18 years of age or older
- Have been diagnosed with metastatic NSCLC
- Have EGFR exon19del or EGFR L858R mutation
- Must have progressed on or after local standard of care systemic anti-cancer therapy, including a 3<sup>rd</sup>-generation EGFR TKI and after platinum-based chemotherapy
- Your most recent line of therapy must not have included an EGFR inhibitor

Additional criteria will apply. Study-required visits, tests and medications may be provided. In addition, reimbursement for study-required travel or expenses may be available.

## Can I change my mind about study participation?

Yes, you can leave the study at any time and for any reason. Even if you start receiving the investigational medication combination, you can choose to leave this study.

## Additional study information

If you would like to speak with someone about this study or your potential participation, please contact the study site staff or your local cancer care provider for additional support.